VIR · Vir Biotechnology, Inc. · Documents
Market Cap
$1.80B
Shares
169.22M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-08-05 | — | |
| 10-Q | 2026-08-05 | 2026-06-30 | |
| 8-K | 2026-07-24 | 2026-07-20 | |
| Investor Event Transcript | 2026-06-30 | — | |
| 8-K | 2026-06-10 | 2026-06-09 | |
| 8-K | 2026-05-28 | 2026-05-25 | |
| 10-Q | 2026-05-07 | 2026-03-31 | |
| 8-K | 2026-05-06 | — | |
| DEF 14A | 2026-04-16 | 2025-12-31 | |
| 8-K | 2026-04-10 | 2026-04-07 | |
| Investor Event Transcript | 2026-03-31 | — | |
| 8-K | 2026-03-04 | — | |
| 8-K | 2026-03-02 | 2026-02-26 | |
| 8-K | 2026-02-26 | 2026-02-25 | |
| 10-K | 2026-02-23 | 2025-12-31 | |
| 8-K | 2026-02-23 | 2026-02-19 | |
| 8-K | 2026-01-12 | — | |
| Investor Event Transcript | 2025-12-31 | — | |
| 8-K | 2025-12-16 | — | |
| 8-K | 2025-11-05 | — | |
| 10-Q | 2025-11-05 | 2025-09-30 | |
| 10-Q | 2025-08-06 | 2025-06-30 | |
| 8-K | 2025-08-06 | — | |
| 8-K | 2025-07-24 | — | |
| 8-K | 2025-05-29 | — | |
| 8-K | 2025-05-09 | — | |
| 10-Q | 2025-05-08 | 2025-03-31 | |
| 8-K | 2025-05-07 | — | |
| DEF 14A | 2025-04-17 | 2025-05-29 | |
| 10-K | 2025-02-27 | 2024-12-31 | |
| 8-K | 2025-02-26 | — | |
| 8-K | 2025-01-30 | 2025-01-24 | |
| 8-K | 2025-01-08 | — | |
| 10-Q | 2024-11-04 | 2024-09-30 | |
| 8-K | 2024-10-31 | — | |
| 8-K | 2024-09-10 | 2024-09-06 | |
| 8-K | 2024-08-01 | 2024-07-29 | |
| 10-Q | 2024-08-01 | 2024-06-30 | |
| 8-K | 2024-08-01 | 2024-07-31 | |
| 8-K | 2024-06-26 | — | |
| 8-K | 2024-06-05 | — | |
| 8-K | 2024-05-29 | — | |
| 10-Q | 2024-05-03 | 2024-03-31 | |
| 8-K | 2024-05-02 | — | |
| DEF 14A | 2024-04-19 | 2024-05-29 | |
| 8-K | 2024-04-18 | 2024-04-15 | |
| 10-K | 2024-02-26 | 2023-12-31 | |
| 8-K | 2024-02-22 | 2024-02-21 | |
| 8-K | 2024-02-20 | 2024-02-19 | |
| 8-K | 2023-12-13 | — |
Showing 1–50 of 137 filings
Key facts
CIK
1706431
CUSIP
92764N102
13F (30d)
78 filings
78 filers
Visit website
Investor relations